Treat the patient, not just the disease How this shift to precision care happened and why is crucial, because the exact same transformation is now reshaping global trade itself In this new era of ‘precision globalization’, multinational companies must be able to tune the best available. Yet the industry now faces a pivotal question Can china’s rising biotech champions grow into fully global companies capable of competing with the world’s largest pharmaceutical groups? Shares in chinese biotech companies have surged by 110% this year, more than three times as much as their american peers
China’s pharmaceutical industry has quietly evolved from a hub for generics and clinical trials into something more ambitious — a genuine competitor in drug discovery that western giants are now courting to fill gaps left by looming patent expirations worth over $300 billion by 2030.
OPEN
